Risultati per: Diagnosi e trattamento della cardiomiopatia ipertrofica (HCM)
Questo è quello che abbiamo trovato per te
Strategie e criteri per la diagnosi e la gestione della miocardite
Diagnosi e terapia patologie pancreatiche, congresso ad Ancona
Diagnosi e terapia patologie pancreatiche, congresso ad Ancona
L'Ia nuovo salva-cuore, la diagnosi di infarto in 37 secondi
Cardiologi, ‘potrà ridurre la mortalità’. Il nodo sulla responsabilità
'La vita è adesso', in un libro come affrontare la diagnosi di tumore
Pravettoni e Boldrini, ‘la malattia può essere anche un’opportunità di crescita’
Linee guida su diagnosi e gestione del diabete e prediabete
L'infettivologo Rezza: la misteriosa malattia in Congo ancora limitata ma si aspetta la diagnosi
“Preoccupa alta letalità, capire se è un elemento noto o nuovo”
Linea guida sulla diagnosi, monitoraggio e gestione dell’asma
Diagnosi e gestione della Leucemia Mieloide Cronica (LMC) negli adulti
Hiv, crescono le nuove diagnosi in Italia
Nel 2023 tornati ai livelli pre covid. Maschi i più colpiti
Alzheimer, Irccs S. Raffaele è diventato un centro ricerca e diagnosi precoce
Focus anche sul trattamento innovativo e riabilitativo
Linee guida italiane su diagnosi e gestione del malato di celiachia: cosa cambia?
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM
Circulation, Ahead of Print. Background: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.Methods: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128.Results: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction